The two-year research grant comes through funding from the Combat Casualty Care Research Program. The funding will be used to develop and test CytoSorbents HemoDefend-BGA product designed to remove anti-A and anti-B antibodies from plasma to create universal plasma, according to a Sept. 9 CytoSorbents news release.
“Our HemoDefend-BGA program has the potential to address a global need for universal plasma in both civilian and combat casualty care. This priority initiative continues to advance, benefitting from more than $11M in government contracts,” CytoSorbents President and COO Vincent Capponi said. “Once the pre-clinical study and requisite benchtop testing are successfully completed, we plan to file a U.S. FDA pre-submission package to pursue human clinical trials with the goal of bringing this life-saving technology to the market.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
